Donald “DK” Strickland joined CellCentric as a US-based medical consultant in November 2021.
DK studied a combined 6-year BA/MD programme at the University of Missouri-Kansas City, before taking his residency in Pediatrics at the Children’s Mercy Hospital in Kansas City. He went on to a haematology/oncology fellowship at Duke University. Following faculty positions at the University of Missouri-Columbia and St. Jude Children’s Research Hospital, he joined a private medical oncology/hematology practice in Memphis, TN, to organize and oversee their clinical research programmes.
DK subsequently joined Genentech Oncology initially as National Liaison shortly after the U.S. commercial approval of bevacizumab, and then later becoming a Medical Director for bevacizumab in the treatment of lung cancer. Following work at PRA International, he spent 8 years at Sarah Cannon Development Innovations, with a specific focus in early-phase oncology and particularly first-in-human trials.